Cough - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Cough - Pipeline Review, H2 2018’, provides an overview of the Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cough

- The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Cough therapeutics and enlists all their major and minor projects

- The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Cough

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cough

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alitair Pharmaceuticals Inc

Alveonix AG

AstraZeneca Plc

Bayer AG

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec AG

GlaxoSmithKline Plc

Grunenthal GmbH ...

Alitair Pharmaceuticals Inc

Alveonix AG

AstraZeneca Plc

Bayer AG

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec AG

GlaxoSmithKline Plc

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Menlo Therapeutics Inc

Merck & Co Inc

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Shionogi & Co Ltd

SolAeroMed Inc

Tris Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cough – Overview

Cough – Therapeutics Development

Pipeline Overview

Pipeline by Companies ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cough – Overview

Cough – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cough – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cough – Companies Involved in Therapeutics Development

Alitair Pharmaceuticals Inc

Alveonix AG

AstraZeneca Plc

Bayer AG

Charleston Laboratories Inc

Conrig Pharma ApS

Develco Pharma Schweiz AG

Evotec AG

GlaxoSmithKline Plc

Grunenthal GmbH

Hyundai Pharmaceutical Co Ltd

Menlo Therapeutics Inc

Merck & Co Inc

Orbis Biosciences Inc

Patara Pharma Inc

PhytoHealth Corp

Shionogi & Co Ltd

SolAeroMed Inc

Tris Pharma Inc

Cough – Drug Profiles

(codeine + guaifenesin) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(guaifenesin + hydrocodone) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-8 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1817080 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1902607 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

benzonatate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bradanicline – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-05 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-06 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-07 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCP-08 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gefapixant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2798745 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guaifenesin ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrocodone bitartrate + Undisclosed drug – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lesogaberan – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levodropropizine CR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORB-110 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orvepitant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pemirolast sodium – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHCA-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1226 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-600918 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Cough – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-015 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cough – Dormant Projects

Cough – Discontinued Products

Cough – Product Development Milestones

Featured News & Press Releases

Jul 19, 2018: BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937

Jul 19, 2018: Evotec Receives Milestone Payment For Start Of Phase II Trial In Its Multi-Target Alliance With Bayer

Jul 09, 2018: BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937

Jun 27, 2018: BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium

Jun 20, 2018: BELLUS Health to Present at the 2018 International Cough Symposium

Feb 20, 2018: Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology

Oct 26, 2017: Menlo Therapeutics Initiates Enrollment in Phase 2 Clinical Trial with Serlopitant for Refractory Chronic Cough

Oct 17, 2017: Menlo Therapeutics Expands its Management Team

Sep 21, 2017: Patara Pharmas Phase 2 Study Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Mediciney Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Medicine

Sep 18, 2017: BELLUS Health's BLU-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models

Sep 11, 2017: Attenua Announces Release of Data Demonstrating that ATA-101 is Antitussive in Guinea Pigs

May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough

Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference

Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough

Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cough, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Cough, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cough – Pipeline by Alitair Pharmaceuticals Inc, H2 2018

Cough – Pipeline by Alveonix AG, H2 2018

Cough – Pipeline by AstraZeneca Plc, H2 2018

Cough – Pipeline by Bayer AG, H2 2018

Cough – Pipeline by Charleston Laboratories Inc, H2 2018

Cough – Pipeline by Conrig Pharma ApS, H2 2018

Cough – Pipeline by Develco Pharma Schweiz AG, H2 2018

Cough – Pipeline by Evotec AG, H2 2018

Cough – Pipeline by GlaxoSmithKline Plc, H2 2018

Cough – Pipeline by Grunenthal GmbH, H2 2018

Cough – Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018

Cough – Pipeline by Menlo Therapeutics Inc, H2 2018

Cough – Pipeline by Merck & Co Inc, H2 2018

Cough – Pipeline by Orbis Biosciences Inc, H2 2018

Cough – Pipeline by Patara Pharma Inc, H2 2018

Cough – Pipeline by PhytoHealth Corp, H2 2018

Cough – Pipeline by Shionogi & Co Ltd, H2 2018

Cough – Pipeline by SolAeroMed Inc, H2 2018

Cough – Pipeline by Tris Pharma Inc, H2 2018

Cough – Dormant Projects, H2 2018

Cough – Dormant Projects, H2 2018 (Contd..1), H2 2018

Cough – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Cough, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by ...

List of Figures

Number of Products under Development for Cough, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports